JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K. B.
Right arrow Articles by Hosey, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K. B.
Right arrow Articles by Hosey, M. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 13, 9284-9289, March 31, 2000


Arrestin Binding to the M2 Muscarinic Acetylcholine Receptor Is Precluded by an Inhibitory Element in the Third Intracellular Loop of the Receptor*

Katharine B. LeeDagger §, Judith A. PtasienskiDagger , Robin Pals-RylaarsdamDagger ||, Vsevolod V. Gurevich**, and M. Marlene HoseyDagger §Dagger Dagger

From the Dagger  Department of Molecular Pharmacology and Biological Chemistry and the § Institute for Neuroscience, Northwestern University Medical School, Chicago, Illinois 60611 and the ** Ralph and Muriel Roberts Laboratory for Vision Science, Sun Health Research Institute, Sun City, Arizona 85732

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Desensitization of G protein-coupled receptors (GPCRs) involves the binding of members of the family of arrestins to the receptors. In the model system involving the visual GPCR rhodopsin, activation and phosphorylation of rhodopsin is thought to convert arrestin from a low to high affinity binding state. Phosphorylation of the M2 muscarinic acetylcholine receptor (mAChR) has been shown to be required for binding of arrestins 2 and 3 in vitro and for arrestin-enhanced internalization in intact cells (Pals-Rylaarsdam, R., and Hosey, M. M. (1997) J. Biol. Chem. 272, 14152-14158). For the M2 mAChR, arrestin binding requires phosphorylation at multiple serine and threonine residues at amino acids 307-311 in the third intracellular (i3) loop. Here, we have investigated the molecular basis for the requirement of receptor phosphorylation for arrestin binding. Constructs of arrestin 2 that can bind to other GPCRs in a phosphorylation-independent manner were unable to interact with a mutant M2 mAChR in which the Ser/Thr residues at 307-311 were mutated to alanines. However, although phosphorylation-deficient mutants of the M2 mAChR that lacked 50-157 amino acids from the i3 loop were unable to undergo agonist-dependent internalization when expressed alone in tsA201 cells, co-expression of arrestin 2 or 3 restored agonist-dependent internalization. Furthermore, a deletion of only 15 amino acids (amino acids 304-319) was sufficient to allow for phosphorylation-independent arrestin-receptor interaction. These results indicate that phosphorylation at residues 307-311 does not appear to be required to activate arrestin into a high affinity binding state. Instead, phosphorylation at residues 307-311 appears to facilitate the removal of an inhibitory constraint that precludes receptor-arrestin association in the absence of receptor phosphorylation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

G protein-coupled receptors (GPCRs)1 are membrane proteins that respond to a wide variety of stimuli, including sensory signals, hormones, and neurotransmitters. The ability of GPCRs to initiate signaling cascades decreases over time of exposure to agonist in a process known as desensitization (reviewed in Refs. 1 and 2). Desensitization has been most extensively studied for the visual GPCR rhodopsin (3). Within seconds following its activation, rhodopsin is phosphorylated on its C terminus in an agonist-dependent manner by rhodopsin kinase (4). This phosphorylation induces proteins termed arrestins to bind to rhodopsin and preclude the ability of rhodopsin to interact with the G protein transducin (5, 6).

Arrestins form a highly conserved family of cytosolic proteins. Arrestins 1 and 4 are found within the visual system (7, 8). Arrestins 2 and 3 are expressed ubiquitously throughout the body (9, 10) and serve multiple functions, including acting as adapters that target GPCRs to clathrin-coated pits for internalization (11). The binding of arrestins to GPCRs is thought to require both the activation and phosphorylation of the GPCRs (12). Based on evidence from both the crystal structure and mutagenesis studies on arrestin 1, a mechanism for arrestin interaction with rhodopsin has been described (12-17). A highly basic set of residues in arrestin 1, which has been shown to be responsible for recognition of phosphorylated rhodopsin, forms intramolecular charge-charge interactions that are disrupted by the phosphorylated C terminus of rhodopsin. This destabilizes the basal state of arrestin and causes arrestin to undergo a conformational change that enables binding to the activated receptor (12, 17, 18).

The events underlying the interaction of arrestins with other GPCRs have been less well studied. The M2 muscarinic acetylcholine receptor (mAChR) undergoes agonist-dependent phosphorylation within its third intracellular (i3) loop (19, 20). Phosphorylation of the M2 mAChR at multiple Ser/Thr residues in amino acids 307-311 (the C cluster) is required for desensitization and for arrestin binding both in vitro and in intact cells (20, 21), whereas phosphorylation at alternative sites (residues 286-291, the N cluster) can occur but has no apparent role in desensitization or arrestin binding (20). In the present study, we have sought to understand the role of phosphorylation of the M2 mAChR by using constructs of arrestin 2 that have been reported to interact with other GPCRs in a phosphorylation-independent manner. We have also tested whether the role of phosphorylation is to activate arrestin or change the conformation of the M2 mAChR in order to allow arrestin to bind to and interact with the receptor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- Dulbecco's modified Eagle's medium and penicillin-streptomycin were purchased from Mediatech. Fetal bovine serum was purchased from Life Technologies, Inc. Hepes-buffered Dulbecco's modified Eagle's medium was obtained from Sigma. N-[3H]Methylscopolamine was purchased from NEN Life Science Products. Anti-arrestin 2 antibody was a generous gift from Jeffrey Benovic (Thomas Jefferson University).

Deletion Mutagenesis-- Creation of the NDelta DENDEN receptor mutant was performed by deleting residues 304-319 in the vector construct of the N cluster mutant (M2 NAla-4 mAChR pCR3 (20) using the QuickChange site-directed mutagenesis kit (Stratagene) as described by the manufacturer's instructions.

Cell Culture and Transfection-- Human embryonic kidney cells stably expressing simian virus 40 large T antigen (HEK-tsA201 cells) were cultured as described (22). HEK-tsA201 cells were transfected using the calcium phosphate precipitation method followed by a rinse with 4 ml of culture medium and incubated with fresh culture medium until cells were utilized for assays 48-72 h posttransfection. Cells were transfected with 10 µg of receptor cDNAs and 5 µg of bovine arrestin 2 or 3 cDNA.

Receptor Internalization Assay-- Changes in the number of mAChRs present on the cell surface as a function of time of agonist exposure were measured using the hydrophilic radioligand N-[3H]methylscopolamine as described previously (22). The cells used in these experiments expressed approximately 0.5-1 pmol of receptor/mg of protein at the cell surface. Data analysis was performed using GraphPad Prism software. Statistical significance was determined using Student's t test.

Immunoblot Analysis-- The expression of arrestins 2 and 3 from the various constructs used in this study was analyzed by Western blotting as described previously (22). In brief, 100 µg of protein from total cellular lysates was loaded onto SDS-acrylamide (8%) gels, transferred to nitrocellulose, and subjected to immunoblotting using antibodies raised in rabbit against arrestin 2.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Effect of Phosphorylation-independent Arrestin Constructs on Internalization of M2 mAChRs-- The ability of the M2 mAChRs to interact with arrestins is dependent on the phosphorylation of Ser/Thr residues in the sequence TVSTS in residues 307-311 (the C cluster) (21). Mutation of this sequence to AVAAA (the C cluster mutant, Fig. 1) results in a receptor that signals normally (20) and internalizes in an arrestin-independent pathway similar to that of the wild-type M2 mAChR (20, 21) but has a greatly impaired ability to interact with arrestins 2 and 3 both in vitro and in intact cells (21). Based on the model developed for rhodopsin-visual arrestin 1 interactions (16, 17), it was possible that the inability of the C cluster mutant to interact with arrestins was due to its inability to activate arrestin 2 into a high affinity conformation that could subsequently bind to the receptors. To test this, we utilized arrestin 2 mutants that can interact with other GPCRs in a phosphorylation-independent but activation-dependent manner (23). We used internalization assays to measure arrestin-receptor interaction, as previous studies have shown that the overexpression of either arrestin 2 or arrestin 3 enhanced the rate and extent of internalization of the M2 mAChR compared with that observed when the receptors were expressed alone (21). In HEK293 cells or tsA201 cells, in the absence of overexpression of arrestins, the M2 mAChR internalizes via an arrestin- and dynamin-independent pathway, and this pathway of internalization is facilitated by phosphorylation at either the N or C cluster (20, 21). Consequently, wild-type and N or C cluster mutants internalize similarly via the arrestin-independent pathway, whereas mutation of both the N and C cluster mutants leads to severe disruption of this yet to be identified internalization pathway (20, 21). If arrestin 2 or 3 is co-expressed with the M2 mAChRs in these cells, the receptors also can internalize by an arrestin-dependent pathway (21). This arrestin-dependent component of internalization requires phosphorylation at the C cluster, whereas phosphorylation at the N cluster cannot support arrestin-dependent internalization (21). For the studies described below, it is important to note that it has been demonstrated previously that the overexpression of arrestins does not redirect all the receptors to the arrestin-independent pathway and that only the fractional increase in internalization that is observed upon arrestin expression represents the arrestin-dependent pathway (21).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic models of M2 mAChR constructs used. A, diagram of the i3 loop of the M2 mAChR highlighting the domains analyzed in the present study. The positions of the N cluster, C cluster, and DENDEN elements are depicted by boldface lines. B, the M2 mAChR i3 loop extends from residue 208 to residue 387 (33). The N cluster mutant has the STSVS at residues 286-291 mutated to AAAVA, whereas the C cluster mutant has the TVSTS at residues 307-311 mutated to AVAAA (20). M2Delta PP is a receptor missing residues 223-380.2 The M2Delta 2 mutant receptor is missing residues 250-323, and the M2Delta 1 mutant receptor is missing residues 282-323 (19). The NDelta DENDEN contains a mutation of the N cluster and the DENDEN deletion of amino acids 304-319. TM5 and TM6 refer to transmembrane domains 5 and 6, which surround the i3 loop.

The internalization of the M2 receptor, when transiently expressed alone in HEK-tsA201 cells, was maximal within 30 min of agonist exposure and reached an extent of 27 ± 7% (Fig. 2A). Upon co-expression of wild-type arrestin 2, the extent of internalization was enhanced approximately 3-fold after 60 min of agonist exposure (Fig. 2A), consistent with previous results (21). The phosphorylation-independent constructs arrestin 2(R169E) and arrestin 2(1-382) (23) also enhanced the extent of internalization of the M2 mAChRs to a similar extent as wild-type arrestin 2 (Fig. 2A). In marked contrast, the internalization of the C cluster mutant was not increased significantly by the overexpression of wild-type arrestin (Fig. 2B), consistent with previous results (21). Surprisingly, however, the internalization of the C cluster mutant was also not increased by the phosphorylation-independent arrestin constructs at any time point during the internalization assay (Fig. 2B). If phosphorylation of the C cluster was required to activate arrestin into a high affinity conformation, we expected the phosphorylation-independent arrestin constructs to interact with the C cluster mutant. These phosphorylation-independent constructs of arrestin have been previously demonstrated to interact with phosphorylation-deficient constructs of beta 2-adrenergic and delta -opioid receptors (23). As these arrestin constructs did not interact with the C cluster mutant of the M2 mAChRs, the results suggested that phosphorylation at the C cluster may be playing a previously unappreciated role.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of phosphorylation-independent arrestin constructs on internalization of the wild-type and C cluster mutant M2 mAChR. TsA201 cells were transiently transfected as described under "Experimental Procedures." Internalization was measured as the loss of N-[3H]methylscopolamine binding to the cell surface as a function of time (minutes) in the presence of 1 mM carbachol (CCh). A, effect of arrestin 2 (arr2), arrestin 2(R169E), and arrestin 2(1-382) overexpression on the agonist-induced internalization of wild-type M2 mAChR. B, effect of arrestin 2, arrestin 2(R169E), arrestin 2(1-382) overexpression on internalization of the C cluster mutant M2 mAChR. The expression of each arrestin 2 construct was verified by Western blotting (data not shown). Results are from 5-8 independent experiments. *, p < 0.05 using Student's t test.

Role of the M2 mAChR i3 Loop in Promoting Arrestin-Receptor Interaction-- The i3 loops of the mAChRs play important roles in arrestin-receptor interactions, because the transfer of the i3 loop from the arrestin-sensitive M2 mAChR conferred arrestin sensitivity to the arrestin-insensitive M3 mAChR (22). We postulated that the ability of the M3/M2i3 chimera to respond to overexpressed arrestin (22) could be due to the existence of a high affinity arrestin binding site found within the M2 mAChR i3 loop. Based on the lack of interaction of the phosphorylation-independent arrestin constructs with the C cluster mutant, we further hypothesized that the i3 loop also contained an inhibitory element and that phosphorylation of the Ser/Thr residues at residues 307-311 was required to reverse the inhibition to allow arrestin binding.

To further test the role of the i3 loop in arrestin interactions, we used a mutant containing only a minimal amount of the i3 loop. This mutant receptor, designated M2Delta PP, is able to couple to G proteins and signals normally,2 even though it lacks most of the i3 loop, specifically residues 223-380 (Fig. 1). This "minimal" receptor has lost all of the known phosphorylation sites within the i3 loop (19, 20). We anticipated that either 1) this receptor would be unable to interact with arrestin because it was phosphorylation-deficient and lacked most of the i3 loop, which appeared to be important for conferring arrestin sensitivity (22); or 2) if an inhibitory element exists in the i3 loop whose inhibitory influence is reversed upon phosphorylation exists in the i3 loop, then removal of the i3 loop might remove both the inhibitory element and the phosphorylation sites and thus create a receptor that can interact with overexpressed arrestin, independently of the phosphorylation state of the receptor. The M2Delta PP receptor, like other phosphorylation-deficient receptors (20, 21), was unable to internalize when transiently expressed alone in tsA201 cells (Fig. 3A). However, upon co-expression with arrestin 2 or arrestin 3, this receptor internalized to an extent of approximately 50% (Fig. 3A), in a manner that was very similar to that seen with the WT M2 mAChR in the presence of arrestin 2 or 3 (compare Fig. 3A with Fig. 2A). These results indicated that the i3 loop of the M2 mAChR was not absolutely necessary for arrestin interaction with the M2 mAChR and suggested that the i3 loop may contain an inhibitory element that precludes receptor-arrestin interaction in the absence of phosphorylation of the C cluster.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Internalization of mutant M2 or M3 mAChR that contain minimal portions of the i3 loops. TsA201 cells were transfected and treated as described under "Experimental Procedures." A, effect of arrestin 2 (arr2) or arrestin 3 (arr3) overexpression on the internalization of M2Delta PP mutant mAChR. B, effect of arrestin 2 or 3 overexpression on internalization of the M3Delta LM. Data are from 5-8 experiments. *, p < 0.05 using Student's t test.

We also examined the ability of a minimal M3 mAChR to interact with overexpressed arrestin. Transfer of the M3i3 loop to the M2 mAChR is sufficient to inhibit M2 mAChR-arrestin interaction (22). We wondered whether the M3i3 loop was precluding the ability of the M3 mAChR to interact with overexpressed arrestin. To examine this possibility, we used an M3 mAChR that also lacks its i3 loop, M3Delta LM, (24). However, this receptor was unable to interact with overexpressed arrestins 2 or 3 (Fig. 3B) suggesting that other factors contribute to the arrestin insensitivity of this receptor (22, 25). Arrestin 3 actually appeared to inhibit the internalization of the M3Delta LM receptor; however, this inhibition was not statistically significant.

To further define the portions of the i3 loop in the M2 mAChR that contain the inhibitory element(s), we prepared and analyzed the ability of additional deletion mutants of the M2 mAChR to respond to overexpressed arrestins 2 and 3. M2Delta 2 is a mutant containing a deletion of residues 250-323 of the i3 loop, whereas M2Delta 1 is a slightly smaller deletion mutant with a deletion of residues 282-323 (Fig. 1) (19). These mutant receptors are both unable to undergo agonist-dependent phosphorylation (19). Like the M2Delta PP mAChR, both of these receptors were unable to internalize in tsA201 cells when transiently expressed alone (Fig. 4, A and B). However, these deletion mutants were arrestin-sensitive, as both receptors exhibited appreciable internalization when co-expressed with either arrestin 2 or 3 (Fig. 4, A and B). Thus, the results obtained with these receptors that contain smaller i3 loop deletions than the minimal mutant also suggested that the removal of an inhibitory element in the i3 loop allowed for phosphorylation-independent interaction with arrestins.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of arrestins 2 and 3 on the internalization of M2 mAChR mutants that contain smaller deletions within their i3 loops. Experiments were performed as in Figs. 2 and 3. A, internalization of an M2 mAChR missing residues 250-323 (M2Delta 2) in the absence and presence of overexpressed arrestin 2 (arr2) and arrestin 3 (arr3). B, internalization of an M2 mAChR missing residues 282-323 (M2Delta 1) in the absence and presence of overexpressed arrestins 2 and 3. C, internalization of an N cluster mutant M2 mAChR missing residues 304-319 (NDelta DENDEN) in the absence and presence of overexpressed arrestins 2 and 3. Data are from 4-11 experiments. *, p < 0.05 using Student's t test.

In order to characterize more specifically which residues within the i3 loop contributed to the proposed inhibitory element, we characterized a mutant in which the residues immediately surrounding the phosphorylation sites in the C cluster were deleted. This mutant, referred to as NDelta DENDEN, lacks residues 304-319 of the wild-type M2 mAChR (Fig. 1), which removes the C cluster and several negative amino acid residues surrounding the C cluster (Fig. 1A). In addition, this mutant has its Ser/Thr residues at the N cluster (residues 286-291) mutated to alanines to remove any effect of phosphorylation (20). We chose to make the DENDEN mutant in the context of the N cluster mutant so that the receptor would be phosphorylation-deficient and not internalize via the arrestin-independent pathway. We anticipated that this would allow for a "cleaner" interpretation of any effects of arrestins. We postulated that the NDelta DENDEN mutant would only be able to respond to arrestin if the deletion of residues 304-319 removed the inhibitory element. The NDelta DENDEN mutant, when expressed alone, did not undergo agonist-dependent internalization (Fig. 4C), which was similar to other phosphorylation-deficient receptor mutants. However, the NDelta DENDEN deletion mutant showed extensive and rapid internalization when co-expressed with arrestin 2 and 3 (Fig. 4C). These results indicated that residues 304-319 contained an inhibitory element that precludes arrestin-receptor interaction in the absence of phosphorylation at residues 307-311. When the Ser/Thr residues in the C cluster are intact and phosphorylated, we hypothesize that this leads to a functional neutralization of the inhibitory constraints. Future studies will resolve how the Ser/Thr residues and/or the surrounding amino acids contribute to the inhibition of receptor-arrestin interaction.

The present results provide novel insights into the interaction of GPCRs and arrestins. In the well studied model of arrestin 1 interaction with visual rhodopsin, it has been proposed that arrestin 1 exists in an inactive state and that receptor activation and the subsequent phosphorylation of the C terminus of rhodopsin is required to disrupt this closed state (16, 17). This leads to a reorientation of the arrestin molecule that can now bind to phosphorylated and activated rhodopsin (26-29). Interestingly, studies have shown that C-terminally truncated rhodopsin mutants that lack phosphorylation sites can also bind to arrestin, but this requires prior "activation" of arrestin (30). Thus, if arrestin has been released from its inactive state by the binding of a phosphorylated synthetic peptide of the C terminus of rhodopsin (30) or by an appropriate mutation of arrestin that renders it phosphorylation-independent (16), binding to activated rhodopsin can occur. However, in the absence of permutations that cause activation of arrestin 1, nonphosphorylated but activated mutants of rhodopsin are unable to bind to arrestin 1 (16, 30).

Our data suggest that very different mechanisms govern the interaction of the M2 mAChRs with nonvisual arrestins 2 and 3. First, we found that two mutant arrestins that are able to interact with beta 2-adrenergic and delta -opioid receptors, regardless of the phosphorylation state of these GPCRs (23), do not bind to the M2 mAChRs unless the receptors are phosphorylated on Ser/Thr residues in the C cluster. Therefore, even though the phosphorylation-independent mutants of arrestin 2 are thought to exist in a more activated state than the wild-type arrestin 2 (23), these arrestin constructs were unable to bind to the M2 mAChR in the absence of specific phosphorylation at the C cluster.

Second, we demonstrated that phosphorylation-deficient mutants of the M2 mAChR can bind to arrestins 2 and 3 and, importantly, that this occurred in the absence of any prior conversion of these arrestins from an inactive to active state. Thus, mutants of the M2 mAChR that lack significant amounts of the i3 loop, as well as the NDelta DENDEN mutant, which lacks the C cluster and surrounding amino acids, can efficiently interact with arrestins 2 and 3 in intact cells. These results suggested that an inhibitory element contained within the DENDEN sequence normally functions to suppress interaction with arrestins. Deletion of this fragment in the context of the N cluster mutant yielded a receptor that was phosphorylation-deficient but interacted well with arrestins 2 and 3. We propose that in the wild-type receptor, upon phosphorylation of the residues in the C cluster within the DENDEN sequence, the inhibitory constraints are relieved to allow for functional interaction with arrestin 2 or 3. We cannot exclude that there may be other "activating" domains in other cytoplasmic portions of the M2 mAChR that serve to convert arrestin 2 or 3 from inactive to active forms. If, however, such activating domains exist within the M2 mAChR, they are not dependent upon phosphorylation for their function.

Although phosphorylation of specific residues was necessary for arrestins 2 and 3 to interact with the wild-type M2 mAChR, we report here the surprising finding that the i3 loop of the M2 mAChR was not necessary for the receptor-arrestin interaction. This result was unexpected given previous results that indicated that the M2i3 loop was sufficient to confer arrestin sensitivity to the arrestin-insensitive M3 mAChR (22). This latter finding indicated that there are sufficient arrestin interaction domains located within the M2i3 loop to promote arrestin binding to the M3 mAChR. However, the present results with mutants that lack most of the i3 loop suggest that the M2 mAChRs must also contain binding sites within other intracellular loops that can support binding to overexpressed arrestin (Fig. 2). These results also suggested that the M3i3 loop inhibits the ability of these other M2 mAChR binding sites from interacting with overexpressed arrestin because transfer of the M3i3 loop to the M2 mAChR results in an arrestin-insensitive receptor (22). Our results, taken together with others, indicate that there are likely to be multiple molecular events that regulate the interactions of GPCRs and arrestins (31, 32). Future experiments will be performed to investigate the specific amino acids that contribute to the inhibitory element that impedes arrestin-M2 mAChR interaction in the absence of phosphorylation and the domains of the M2 mAChR that are able to interact with arrestin 2 in an intact cell.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL 50121 (to M. M. H.) and EY 11500 (to V. V. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by National Service Research Award Training Grant T32GM08061.

|| Present address: Children's Memorial Inst. for Education and Research, Chicago, IL 60614. Supported by a Howard Hughes Medical Institute Predoctoral Fellowship.

Dagger Dagger To whom correspondence should be addressed: Dept. of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, 303 E. Chicago Ave., S215, Chicago, IL 60611. Tel.: 312-503-3692; Fax: 312-503-5349; E-mail: mhosey@nwu.edu.

2 Mark Dell'Acqua, personal communication.

    ABBREVIATIONS

The abbreviations used are: GPCR, G protein-coupled receptor; mAChR, muscarinic acetylcholine receptor; i3 loop, third intracellular loop; HEK, human embryonic kidney.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Bunemann, M., Lee, K. B., Pals-Rylaarsdam, R., Roseberry, A. G., and Hosey, M. M. (1999) Annu. Rev. Physiol. 61, 169-192[CrossRef][Medline] [Order article via Infotrieve]
2. Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 18677-18680[Free Full Text]
3. Molday, R. S. (1998) Invest. Ophthalmol. Vis. Sci. 39, 2491-2513[Medline] [Order article via Infotrieve]
4. Kuhn, H. (1978) Biochemistry 17, 4389-4395[CrossRef][Medline] [Order article via Infotrieve]
5. Kuhn, H., Hall, S. W., and Wilden, U. (1984) FEBS Lett. 176, 473-478[CrossRef][Medline] [Order article via Infotrieve]
6. Wilden, U., Wust, E., Weyand, I., and Kuhn, H. (1986) FEBS Lett. 207, 292-295[CrossRef][Medline] [Order article via Infotrieve]
7. Yamaki, K., Takahashi, Y., Sakuragi, S., and Matsubara, K. (1987) Biochem. Biophys. Res. Commun. 142, 904-910[CrossRef][Medline] [Order article via Infotrieve]
8. Craft, C. M., Whitmore, D. H., and Wiechmann, A. F. (1994) J. Biol. Chem. 269, 4613-4619[Abstract/Free Full Text]
9. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990) Science 248, 1547-1550[Abstract/Free Full Text]
10. Attramadal, H., Arriza, J. L., Aoki, C., Dawson, T. M., Codina, J., Kwatra, M. M., Snyder, S. H., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 17882-17890[Abstract/Free Full Text]
11. Goodman, O. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450[CrossRef][Medline] [Order article via Infotrieve]
12. Gurevich, V. V., and Benovic, J. L. (1993) J. Biol. Chem. 268, 11628-11638[Abstract/Free Full Text]
13. Gurevich, V. V., Chen, C. Y., Kim, C. M., and Benovic, J. L. (1994) J. Biol. Chem. 269, 8721-8727[Abstract/Free Full Text]
14. Gurevich, V. V., and Benovic, J. L. (1995) J. Biol. Chem. 270, 6010-6016[Abstract/Free Full Text]
15. Gurevich, V. V., Dion, S. B., Onorato, J. J., Ptasienski, J., Kim, C. M., Sterne-Marr, R., Hosey, M. M., and Benovic, J. L. (1995) J. Biol. Chem. 270, 720-731[Abstract/Free Full Text]
16. Gurevich, V. V., and Benovic, J. L. (1997) Mol Pharmacol 51, 161-169[Abstract/Free Full Text]
17. Hirsch, J. A., Schubert, C., Gurevich, V. V., and Sigler, P. B. (1999) Cell 97, 257-269[CrossRef][Medline] [Order article via Infotrieve]
18. Schleicher, A., Kuhn, H., and Hofmann, K. P. (1989) Biochemistry 28, 1770-1775[CrossRef][Medline] [Order article via Infotrieve]
19. Pals-Rylaarsdam, R., Xu, Y., Witt-Enderby, P., Benovic, J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270, 29004-29011[Abstract/Free Full Text]
20. Pals-Rylaarsdam, R., and Hosey, M. M. (1997) J. Biol. Chem. 272, 14152-14158[Abstract/Free Full Text]
21. Pals-Rylaarsdam, R., Gurevich, V. V., Lee, K. B., Ptasienski, J. A., Benovic, J. L., and Hosey, M. M. (1997) J. Biol. Chem. 272, 23682-23689[Abstract/Free Full Text]
22. Lee, K. B., Pals-Rylaarsdam, R., Benovic, J. L., and Hosey, M. M. (1998) J. Biol. Chem. 273, 12967-12972[Abstract/Free Full Text]
23. Kovoor, A., Celver, J., Abdryashitov, R. I., Chavkin, C., and Gurevich, V. V. (1999) J. Biol. Chem. 274, 6831-6834[Abstract/Free Full Text]
24. Kunkel, M. T., and Peralta, E. G. (1993) EMBO J. 12, 3809-3815[Medline] [Order article via Infotrieve]
25. Mundell, S. J., Loudon, R. P., and Benovic, J. L. (1999) Biochemistry 38, 8723-8732[CrossRef][Medline] [Order article via Infotrieve]
26. Hargrave, P. A., and McDowell, J. H. (1992) FASEB J 6, 2323-2331[Abstract]
27. Palczewski, K., Buczylko, J., Imami, N. R., McDowell, J. H., and Hargrave, P. A. (1991) J. Biol. Chem. 266, 15334-15339[Abstract/Free Full Text]
28. Palczewski, K., Rispoli, G., and Detwiler, P. B. (1992) Neuron 8, 117-126[CrossRef][Medline] [Order article via Infotrieve]
29. Vishnivetskiy, S. A., Paz, C. L., Schubert, C., Hirsch, J. A., Sigler, P. B., and Gurevich, V. V. (1999) J. Biol. Chem. 274, 11451-11454[Abstract/Free Full Text]
30. McDowell, J. H., Smith, W. C., Miller, R. L., Popp, M. P., Arendt, A., Abdulaeva, G., and Hargrave, P. A. (1999) Biochemistry 38, 6119-6125[CrossRef][Medline] [Order article via Infotrieve]
31. Mukherjee, S., Palczewski, K., Gurevich, V. V., and Hunzicker-Dunn, M. (1999) J. Biol. Chem. 274, 12984-12989[Abstract/Free Full Text]
32. Mukherjee, S., Palczewski, K., Gurevich, V., Benovic, J. L., Banga, J. P., and Hunzicker-Dunn, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 493-498[Abstract/Free Full Text]
33. Peralta, E. G., Ashkenazi, A., Winslow, J. W., Smith, D. H., Ramachandran, J., and Capon, D. J. (1987) EMBO J. 6, 3923-3929[Medline] [Order article via Infotrieve]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
V. V. Gurevich and E. V. Gurevich
Rich Tapestry of G Protein-Coupled Receptor Signaling and Regulatory Mechanisms
Mol. Pharmacol., August 1, 2008; 74(2): 312 - 316.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. H. Oakley, J. A. Olivares-Reyes, C. C. Hudson, F. Flores-Vega, F. M. Dautzenberg, and R. L. Hauger
Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R209 - R222.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Bisello, M. Chorev, M. Rosenblatt, L. Monticelli, D. F. Mierke, and S. L. Ferrari
Selective Ligand-induced Stabilization of Active and Desensitized Parathyroid Hormone Type 1 Receptor Conformations
J. Biol. Chem., October 4, 2002; 277(41): 38524 - 38530.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Chen, D. J. Dupre, C. Le Gouill, M. Rola-Pleszczynski, and J. Stankova
Agonist-induced Internalization of the Platelet-activating Factor Receptor Is Dependent on Arrestins but Independent of G-protein Activation. ROLE OF THE C TERMINUS AND THE (D/N)PXXY MOTIF
J. Biol. Chem., February 22, 2002; 277(9): 7356 - 7362.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. N. Hislop, H. M. Everest, A. Flynn, T. Harding, J. B. Uney, B. E. Troskie, R. P. Millar, and C. A. McArdle
Differential Internalization of Mammalian and Non-mammalian Gonadotropin-releasing Hormone Receptors. UNCOUPLING OF DYNAMIN-DEPENDENT INTERNALIZATION FROM MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING
J. Biol. Chem., October 19, 2001; 276(43): 39685 - 39694.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. S. G. Ferguson
Evolving Concepts in G Protein-Coupled Receptor Endocytosis: The Role in Receptor Desensitization and Signaling
Pharmacol. Rev., March 1, 2001; 53(1): 1 - 24.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. B. Lee, J. A. Ptasienski, M. Bunemann, and M. M. Hosey
Acidic Amino Acids Flanking Phosphorylation Sites in the M2 Muscarinic Receptor Regulate Receptor Phosphorylation, Internalization, and Interaction with Arrestins
J. Biol. Chem., November 10, 2000; 275(46): 35767 - 35777.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kishi and M. Ascoli
Multiple Distant Amino Acid Residues Present in the Serpentine Region of the Follitropin Receptor Modulate the Rate of Agonist-induced Internalization
J. Biol. Chem., September 29, 2000; 275(40): 31030 - 31037.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K. B.
Right arrow Articles by Hosey, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K. B.
Right arrow Articles by Hosey, M. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.